Regulation of Type I Interferon Pro-tumor Effects in Breast Cancer

I 型干扰素促肿瘤效应在乳腺癌中的调节

• 批准号: 10298013
• 负责人: Mei-Yi Wu
• 金额: $ 36.94万
• 依托单位: GEORGE WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-01 至 2026-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10298013
• 关键词: ARID Domain; Ablation; Address; Adjuvant Chemotherapy; Adjuvant Radiotherapy; Affect; Breast Cancer Cell; Breast Cancer Patient; Breast Cancer Treatment; Breast Cancer cell line; CEB1 Gene; Cells; Clinical; DNA Damage; DNA Repair; Data; Development; Excision; Family; Genes; Human; ISG15 gene; Immune; Interferon Type I; Interferons; Intervention; Knock-in Mouse; Knock-out; Knowledge; Lead; Malignant Neoplasms; Mammary Neoplasms; Mediating; Medical; Oncogenic; Operative Surgical Procedures; Outcome; Pathway interactions; Patients; Pharmaceutical Preparations; Proteins; Public Health; Radiation; Regulation; Regulatory Pathway; Relapse; Research; Resistance; Resistance development; Role; STAT1 gene; Signal Pathway; Signal Transduction; Testing; Therapeutic; Treatment Efficacy; antitumor effect; breast cancer progression; breast cancer survival; cancer cell; cancer radiation therapy; cancer therapy; cancer type; chemotherapy; chromatin remodeling; clinical efficacy; genetic signature; hormone therapy; immunoregulation; improved; in vivo; innovation; irradiation; malignant breast neoplasm; mouse model; new therapeutic target; novel therapeutic intervention; pre-clinical; response; standard care; theories; therapy development; therapy resistant; tumor; tumor progression; tumorigenesis

Project Summary/Abstract Adjuvant radiotherapy or chemotherapy is a standard treatment for breast cancer patients after surgical resection of cancer. However, cancer cells commonly develop therapeutic resistance. A crucial factor that decides whether a tumor relapses or responds to these cancer therapies is the dual role of interferon (IFN) in promoting or counteracting cancer progression, respectively. A set of IFN-stimulated genes (ISGs), the so-called “IFN-related DNA damage resistance signature” (IRDS), was recently implicated in resistance to irradiation and chemotherapy in different types of cancers, including breast cancer. While irradiation and some of chemotherapy drugs cause DNA damage in cancer cells, IFN1 induces expression of IRDS that mediates DNA damage resistance to treatments. Therefore, in theory, inhibiting the IFN1 pathway could restore therapeutic sensitivity. However, indiscriminate suppression of IFN1 signaling could also constrain its anti-tumor effects, which will not provide the desired clinical efficacy to patients. Inhibiting the IRDS-mediated pro-tumor activities but reserving the IFN1-induced anti-tumor effects could be a favorable strategy to provide major benefit to patients. To this end, understanding how the IRDS is regulated and how it protects cancer cells against therapies is urgent and important. AT-rich interaction domain 4B (ARID4B) belongs to the ARID family and is a chromatin remodeling protein. Our preliminary data demonstrate that ARID4B is highly expressed in human breast cancer and its high expression is associated with poor clinical outcomes in breast cancer patients. Knockout of ARID4B in breast cancer cell lines and mouse models compromised tumorigenesis. In addition, ablation of ARID4B reduced DNA damage repair and increased sensitivity to irradiation and DNA-damaging drugs in breast cancer cells. Mechanistically, ARID4B is required for IFN1-mediated activation of the STAT1-IRDS axis and regulates PARylation/dePARylation in breast cancer cells. A central hypothesis for this proposal is: The IFN1 pro-tumor effects are determined by ARID4B, because ARID4B is crucial for activation of the IFN1-STAT1-IRDS signaling pathway that regulates PARylation/dePARylation-dependent DNA damage response to promote breast cancer progression and therapeutic resistance to irradiation and DNA-damaging drugs. The hypothesis will be tested by three specific aims: Aim 1. Determine the role of ARID4B on regulation of PARylation/dePARylation- dependent DNA damage response to promote the IFN1-IRDS pro-tumor effects. Aim 2. Identify the mechanism by which ARID4B regulates the IFN-STAT1-IRDS pathway. Aim 3. Preclinical analyses of ARID4B impact on breast cancer resistance to irradiation and DNA-damaging drugs. This study is innovative because it uncovers ARID4B as the specific determinant of IFN pro-tumor effects. This study is significant because analyses of ARID4B function and its regulatory pathway could lead to new therapeutic approaches that improve treatment efficacy and survival for breast cancer patients.

项目总结/文摘